Overactive Bladder Treatment Market Research Report – Forecast to 2027

Global Overactive Bladder Treatment Market Research Report: By Pharmacotherapy (Anticholinergic, Botox, Others), by Non-Pharmacological Treatment (Behavioral Therapy, Others), by Disease (Idiopathic Overactive Bladder, Others) – Global Forecast Till 2027

ID: MRFR/Pharma/4787-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario

The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.

Overactive Bladder (OAB) is a symptom syndrome characterized by urinary urgency. Numerous factors such as the growing prevalence of Overactive Bladder (OAB) coupled with the rising geriatric population, increasing occurrences of Parkinson’s disease, and multiple sclerosis and stroke are likely to drive the growth of the market during the forecast period. For instance, according to the data stated by the Official Foundation of the American Urological Association, in 2016, approximately 33 million Americans had an overactive bladder. It also mentioned that around 30% of men and 40% of women in the US have the symptoms of overactive bladder. Moreover, the development of innovative intravesical therapies and increasing marketing activities by pharma companies contribute to the growth of the market.

Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.

Research Methodology

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


The extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the overactive bladder treatment market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases, and many others.


Company Profiles    



  • Astellas Pharma Inc.

  • Pfizer, Inc.

  • Teva Pharmaceutical

  • Allergan, Plc. 

  • Mylan N.V. 

  • Endo International Plc 

  • Hisamitsu Pharmaceutical Co., Inc.

  • Sanofi S. A.

  • Aurobindo Pharma Limited 

  • Johnson & Johnson

  • Intas Pharmaceuticals Ltd. 

  • Apotex Inc. 

  • Macleods Pharmaceuticals Ltd. 

  • Medtronic PLC

  • Cogentix Medical, Inc.

  • Others


Segmentation


The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.


On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.


The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.


On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.


Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.


The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.


The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.


The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.


Regional Market Summary


The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.


Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.


The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.


The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.


Global Overactive Bladder Treatment Market, by Pharmacotherapy



  • Anticholinergics

  • Solifenacin

  • Oxybutynin

  • Fesoterodine

  • Darifenacin

  • Tolterodine

  • Trospium

  • Others

  • Botox

  • Mirabegron

  • Neurostimulation

  • Others


Global Overactive Bladder Treatment Market, by Non-Pharmacological Treatment



  • Dietary and Fluid Modifications

  • Behavioral Therapy

  • Pelvic Floor Muscle Rehabilitation

  • Others


Global Overactive Bladder Treatment Market, by Disease



  • Idiopathic Overactive Bladder

  • Neurogenic Overactive Bladder

  • Overactive Bladder in Parkinson’s Disease

  • Overactive Bladder in Stroke

  • Overactive Bladder in Multiple Sclerosis

  • Overactive Bladder in Spinal Cord Injury

  • Overactive Bladder in Other Disorders


Global Overactive Bladder Treatment Market, by Region



  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia-Pacific

  • The Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Drug manufacturers, vendors, and distributors

  • Academic and government research institutes

  • Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs)

  • Venture capitalists and investors



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2018-2023: ~ 3.1%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Pharmacotherapy, Non-Pharmacological Treatment, and Disease
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical, Allergan, Plc. , Mylan N.V. , Endo International Plc , Hisamitsu Pharmaceutical Co., Inc., Sanofi S. A., Aurobindo Pharma Limited , Johnson & Johnson, Intas Pharmaceuticals Ltd. , Apotex Inc. , Macleods Pharmaceuticals Ltd. , Medtronic PLC, Cogentix Medical, Inc.
  Key Market Opportunities

  • Development of innovative intravesical therapies
  • Increasing marketing activities by pharma companies
  •   Key Market Drivers

  • Rising geriatric population
  • Increasing occurrences of parkinson’s disease and multiple sclerosis and stroke


  • Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Overactive Bladder Treatment Market, by Pharmacotherapy

    6.1 Introduction

    6.2 Anticholinergics

    6.2.1 Solifenacin

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.2.2 Oxybutynin

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.2.3 Fesoterodine

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.2.4 Darifenacin

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.2.5 Tolterodine

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.2.6 Trospium

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.2.7 Others

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.3 Botox

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.4 Mirabegron

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.5 Neurostimulation

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    6.6 Others

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    Chapter 7. Global Overactive Bladder Treatment Market, by Non-Pharmacological Treatment

    7.1 Introduction

    7.2 Dietary and Fluid Modifications

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    7.3 Behavioral Therapy

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    7.4 Pelvic Floor Muscle Rehabilation

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    7.5 Others

    Chapter 8. Global Overactive Bladder Treatment Market, by Disease

    8.1 Introduction

    8.2 Idiopathic Overactive Bladder

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    8.3 Neurogenic Overactive Bladder

    8.3.1 Overactive Bladder in Parkinson’s Disease

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    8.3.2 Overactive Bladder in Stroke

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    8.3.3 Overactive Bladder in Multiple Scelorsis

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    8.3.4 Overactive Bladder in Spinal Cord Injury

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    8.3.5 Overactive Bladder in Other Disorders

    Market Estimates & Forecast by region, 2020–2027

    Market Estimates & Forecast country, 2020–2027

    Chapter 9. Global Overactive Bladder Treatment Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 U.S.

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 U.K.

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 The Middle East

    9.5.2 Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    Chapter 11. Company Profiles

    11.1 Astellas Pharma Inc.

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials Overview

    11.1.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Pfizer, Inc.

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Teva Pharmaceutical Industries Ltd.

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Allergan, Plc

    11.4.1 Company Overview

    11.4.2 Technologys/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Mylan N.V.

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Endo International Plc

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Hisamitsu Pharmaceutical Co., Inc.

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financial Overview

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Sanofi S. A.

    11.8.1 Overview

    11.8.2 Product/ Technology Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Aurobindo Pharma Limited

    11.9.1 Overview

    11.9.2 Product Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 Johnson & Johnson

    11.10.1 Overview

    11.10.2 Product Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 Intas Pharmaceuticals Ltd.

    11.11.1 Overview

    11.11.2 Product Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Apotex Inc.

    11.12.1 Overview

    11.12.2 Product Overview

    11.12.3 Financials

    11.12.4 Key Developments

    11.12.5 SWOT Analysis

    11.13 Macleods Pharmaceuticals Ltd.

    11.13.1 Overview

    11.13.2 Product Overview

    11.13.3 Financials

    11.13.4 Key Developments

    11.13.5 SWOT Analysis

    11.14 Medtronic Plc

    11.14.1 Overview

    11.14.2 Product Overview

    11.14.3 Financials

    11.14.4 Key Developments

    11.14.5 SWOT Analysis

    11.15 Cogentix Medical, Inc.

    11.14.1 Overview

    11.14.2 Product Overview

    11.14.3 Financials

    11.14.4 Key Developments

    11.14.5 SWOT Analysis

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of the Overactive Bladder Treatment Industry

    Chapter 13 Appendix

    LIST OF TABLES

    Table 1 Global Overactive Bladder Treatment Market Synopsis, 2020–2027

    Table 2 Global Overactive Bladder Treatment Market Estimates and Forecast, 2020–2027, (USD

    Million)

    Table 3 Global Overactive Bladder Treatment Market, by Region, 2020–2027, (USD Million)

    Table 4 Global Overactive Bladder Treatment Market, by Pharmacotherapy, 2020–2027, (USD

    Million)

    Table 5 Global Overactive Bladder Treatment Market, by Method, 2020–2027, (USD Million)

    Table 6 Global Overactive Bladder Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 7 North America Global Overactive Bladder Treatment Market, by Pharmacotherapy,

    2020–2027, (USD Million)

    Table 8 North America Global Overactive Bladder Treatment Market, by Non-Pharmacological Treatment, 2020–2027, (USD Million)

    Table 9 North America Global Overactive Bladder Treatment Market, by Disease, 2020–2027,

    (USD Million)

    Table 10 U.S. Overactive Bladder Treatment Market, by Pharmacotherapy, 2020–2027, (USD

    Million)

    Table 11 U.S. Overactive Bladder Treatment Market, by Non-Pharmacological Treatment, 2020–

    2027, (USD Million)

    Table 12 U.S. Overactive Bladder Treatment Market, by Disease, 2020–2027, (USD Million)

    Table 13 Canada Overactive Bladder Treatment Market,by Pharmacotherapy, 2020–2027, (USD

    Million)

    Table 14 Canada Overactive Bladder Treatment Market, by Non-Pharmacological Treatment,

    2020–2027, (USD Million)

    Table 15 Canada Overactive Bladder Treatment Market, by Disease, 2020–2027, (USD Million)

    Table 16 South America Overactive Bladder Treatment Market, by Pharmacotherapy, 2020–2027,

    (USD Million)

    Table 17 South America Overactive Bladder Treatment Market, by Non-Pharmacological

    Treatment, 2020–2027, (USD Million)

    Table 18 South America Overactive Bladder Treatment Market, by Disease, 2020–2027, (USD

    Million)

    Table 19 Europe Overactive Bladder Treatment Market, by Pharmacotherapy, 2020–2027, (USD

    Million)

    Table 20 Europe Overactive Bladder Treatment Market, by Non-Pharmacological Treatment,

    2020–2027, (USD Million)

    Table 21 Europe Overactive Bladder Treatment Market, by Disease, 2020–2027, (USD Million)

    Table 22 Western Europe Overactive Bladder Treatment Market, by Pharmacotherapy, 2020–

    2027, (USD Million)

    Table 23 Western Europe Overactive Bladder Treatment Market, by Non-Pharmacological

    Treatment, 2020–2027, (USD Million)

    Table 24 Western Europe Overactive Bladder Treatment Market, by Disease, 2020–2027, (USD

    Million)

    Table 25 Eastern Europe Overactive Bladder Treatment Market, by Pharmacotherapy, 2020–2027,

    (USD Million)

    Table 26 Eastern Europe Overactive Bladder Treatment Market, by Non-Pharmacological

    Treatment, 2020–2027, (USD Million)

    Table 27 Eastern Europe Overactive Bladder Treatment Market, by Disease, 2020–2027, (USD

    Million)

    Table 28 Asia Pacific Overactive Bladder Treatment Market, by Pharmacotherapy, 2020–2027,

    (USD Million)

    Table 29 Asia Pacific Overactive Bladder Treatment Market, by Non-Pharmacological Treatment,

    2020–2027, (USD Million)

    Table 30 Asia Pacific Overactive Bladder Treatment Market, by Disease, 2020–2027, (USD

    Million)

    Table 31 Middle East & Africa Overactive Bladder Treatment Market, by Pharmacotherapy, 2020–

    2027, (USD Million)

    Table 32 Middle East & Africa Overactive Bladder Treatment Market, by Non-Pharmacological

    Treatment, 2020–2027, (USD Million)

    Table 33 Middle East & Africa Overactive Bladder Treatment Market, by Disease, 2020–2027,

    (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Overactive Bladder Treatment Market

    Figure 3 Segmentation Market Dynamics for Global Overactive Bladder Treatment Market

    Figure 4 Global Overactive Bladder Treatment Market Share, by Pharmacotherapy, 2020

    Figure 5 Global Overactive Bladder Treatment Market Share, by Non-Pharmacological Treatment,

    2020

    Figure 6 Global Overactive Bladder Treatment Market Share, by Disease, 2020

    Figure 7 Global Overactive Bladder Treatment Market Share, by Region, 2020

    Figure 8 North America Overactive Bladder Treatment Market Share, by Country, 2020

    Figure 9 Europe Overactive Bladder Treatment Market Share, by Country, 2020

    Figure 10 Asia Pacific Overactive Bladder Treatment Market Share, by Country, 2020

    Figure 11 Middle East & Africa Overactive Bladder Treatment Market Share, by Country, 2020

    Figure 12 Global Overactive Bladder Treatment Market: Company Share Analysis, 2020 (%)

    Figure 13 Astellas Pharma Inc.: Key Financials

    Figure 14 Astellas Pharma Inc.: Segmental Revenue

    Figure 15 Astellas Pharma Inc.: Geographical Revenue

    Figure 16 Pfizer, Inc.: Key Financials

    Figure 17 Pfizer, Inc.: Segmental Revenue

    Figure 18 Pfizer, Inc.: Geographical Revenue

    Figure 19 Teva Pharmaceutical Industries Ltd.::Key Financials

    Figure 20 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

    Figure 21 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

    Figure 22 Allergan, Plc: Key Financials

    Figure 23 Allergan, Plc: Segmental Revenue

    Figure 24 Allergan, Plc: Geographical Revenue

    Figure 25 Mylan N.V.:Key Financials

    Figure 26 Mylan N.V.: Segmental Revenue

    Figure 27 Mylan N.V.. Geographical Revenue

    Figure 28 Endo International Plc: Key Financials

    Figure 29 Endo International Plc: Segmental Revenue

    Figure 30 Endo International Plc : Geographical Revenue

    Figure 31 Hisamitsu Pharmaceutical Co., Inc.: Key Financials

    Figure 32 Hisamitsu Pharmaceutical Co., Inc.: Segmental Revenue

    Figure 33 Hisamitsu Pharmaceutical Co., Inc.: Geographical Revenue

    Figure 34 Sanofi S. A.: Key Financials

    Figure 35 Sanofi S. A.: Segmental Revenue

    Figure 36 Sanofi S. A.: Geographical Revenue

    Figure 37 Aurobindo Pharma Limited: Key Financials

    Figure 38 Aurobindo Pharma Limited: Segmental Revenue

    Figure 39 Aurobindo Pharma Limited: Geographical Revenue

    Figure 40 Johnson & Johnson: Key Financials

    Figure 41 Johnson & Johnson: Segmental Revenue

    Figure 42 Johnson & Johnson: Geographical Revenue

    Figure 43 Intas Pharmaceuticals Ltd.: Key Financials

    Figure 44 Intas Pharmaceuticals Ltd. Segmental Revenue

    Figure 45 Intas Pharmaceuticals Ltd.: Geographical Revenue

    Figure 46 Apotex Inc.: Key Financials

    Figure 47 Apotex Inc.: Segmental Revenue

    Figure 48 Apotex Inc.: Geographical Revenue

    Figure 49 Macleods Pharmaceuticals Ltd.: Key Financials

    Figure 50 Macleods Pharmaceuticals Ltd.: Segmental Revenue

    Figure 51 Macleods Pharmaceuticals Ltd.: Geographical Revenue

    Figure 52 Medtronic Plc: Key Financials

    Figure 53 Medtronic Plc: Segmental Revenue

    Figure 54 Medtronic Plc: Geographical Revenue

    Figure 52 Cogentix Medical, Inc.: Key Financials

    Figure 53 Cogentix Medical, Inc: Segmental Revenue

    Figure 54 Cogentix Medical, Inc: Geographical Revenue